Nuvectis Pharma, Inc. terminated its prior at-the-market (ATM) offering program effective July 20, 2026, and entered into a new Open Market Sale Agreement with Jefferies LLC on August 21, 2026. Under the new agreement, the company may offer and sell shares of common stock from time to time through Jefferies acting as sales agent. The offering is part of a new shelf Registration Statement on Form S-3 filed on August 21, 2026, which registers up to $200 million in securities. Jefferies will receive compensation of up to 3.0% of the gross proceeds from any ATM shares sold. Nuvectis Pharma operates in the biotechnology industry and develops pharmaceutical products.

Nuvectis Pharma reported a net loss of $7.0 million for the second quarter ended June 30, 2026, compared to $6.3 million in the prior year period. The company completed a follow-on public offering in July 2026, raising $115 million in gross proceeds and extending its cash runway into the first half of 2029. Cash and cash equivalents stood at $22.2 million as of June 30, 2026. The firm also announced the in-licensing of ex-China rights to two compounds, NXP100 (ciprocopan) and NXP200, from Haisco Pharmaceutical Group. Ciprocopan received marketing approval in China in July 2026 for treating paroxysmal nocturnal hemoglobinuria. The company operates as a clinical-stage biopharmaceutical firm developing therapies for complement-related conditions and oncology.

Nuvectis Pharma, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. to conduct a public offering of 5,000,000 shares of common stock at $20.00 per share. The company expects to receive approximately $93 million in net proceeds, or up to $107 million if underwriters exercise their 30-day option to purchase an additional 750,000 shares. The transaction is expected to close on July 1, 2026. Nuvectis Pharma, Inc. is a pharmaceutical company focused on developing and commercializing therapeutic products.

Nuvectis Pharma, Inc. announced on June 29, 2026, that it is suspending its Sales Agreement with Leerink Partners LLC and reducing the total amount available for sales under the Sales Agreement Prospectus to $5 million. The company will not conduct any share sales under the current agreement unless a new registration statement or prospectus is filed. Nuvectis Pharma, Inc. is a pharmaceutical company focused on the development and commercialization of medicines for neurological and neurological-related disorders.

Nuvectis Pharma, Inc. entered into a license agreement with Haisco Pharmaceutical Group Co., Ltd. to obtain exclusive, royalty-bearing rights for NXP100 (a Complement Factor B inhibitor) and NXP200 (a BRAF inhibitor). The agreement includes a $20 million upfront payment and up to $20 million in initial development milestones, with Haisco is entitled to receive up to $1.4 billion in contingent payments and tiered royalties in the high-single digits to mid-teens based on net sales. The agreement is subject to certain financing conditions. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for complement-mediated diseases and BRAF-mutated malignancies.